Similar Maximum Systemic but not Local Cyclooxygenase-2 Inhibition by 50 mg Lumiracoxib and 90 mg Etoricoxib: A Randomized Controlled Trial in Healthy Subjects-Reference-Cited by-同舟云学术

Similar Maximum Systemic but not Local Cyclooxygenase-2 Inhibition by 50 mg Lumiracoxib and 90 mg Etoricoxib: A Randomized Controlled Trial in Healthy Subjects

Published:2014-01-28 Issue: Volume: Page:
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Felden Lisa,Walter Carmen,Angioni Carlo,Schreiber Yannick,von Hentig Nils,Ferreiros Nerea,Geisslinger Gerd,Lötsch Jörn

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s11095-013-1285-z.pdf

Reference45 articles.

1. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364:675–84.

2. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665–74.

3. Li Y, Slatter JG, Zhang Z, Doss GA, Braun MP, Stearns RA, et al. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab Dispos. 2008;36:469–73.

4. Healthcare products Regulatory Agency. Press release: Prexige (lumiracoxib) licence has been suspended. http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2033078

5. H.C. Government of Canada. Withdrawal of market authorization for Prexige - Health Canada Advisory 2007–10–04. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2007/2007_141-eng.php .